Form 4: Ligand Pharmaceuticals Executive Acquires Shares and Stock Options

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals, reports acquisition of common stock and stock options.

Summary

• On March 4, 2025, Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals, reported transactions involving the company's securities.
• Reardon acquired 6,415 shares of common stock at $0.00, increasing his holdings to 34,783 shares.
• He also acquired 28,043 employee stock options with an exercise price of $115.26, exercisable starting September 4, 2025, and expiring on March 4, 2035.
• The stock options vest over time, with an initial 12.5% vesting six months after the grant date, followed by monthly installments.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by an executive suggests confidence, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into a company's prospects. Acquisitions by executives are generally viewed positively.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates